NCT07156617 - A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

PROCEDURE

Interventional therapy

DRUG

Systemic therapy

Targeted Therapy drugs include but are not limited to Lenvatinib, Apatinib, etc. Immunotherapy drugs include but are not limited to Camrelizumab, Tislelizumab

Trial Locations (14)

Unknown

The Second Affiliated Hospital of Hainan Medical Universsity, Haikou

Xingtai No.5 Hospital, Xingtai

Deng zhou People's Hospital, Dengzhou

The Second People's Hospital of Jiaozuo, Jiaozuo

Huai He Hospital of Henan University, Kaifeng

Luo Yang Central Hospital, Luoyang

The First Affiliated Hospital of Henan University of science and Technology, Luoyang

First People's Hospital of Shangqiu, Shangqiu

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Zhou Kou Central Hospital, Zhoukou

Wuxi No.5 People's Hospital, Wuxi

Jiangxi Provincial People's Hospitail, Nanchang

The First Affiliated Hospital of Nanchang University, Nanchang

Second People's Hospital of Jiaozuo, Jiaozuo

All Listed Sponsors

lead

Xuhua Duan

OTHER